dilated cardiomyopathy 1EE

disease
On this page

Also known as cardiomyopathy, dilated, 1EEcardiomyopathy, dilated, type 1EeCMD1EEdilated cardiomyopathy type 1EEfamilial isolated dilated cardiomyopathy caused by mutation in MYH6MYH6 familial isolated dilated cardiomyopathy

Summary

dilated cardiomyopathy 1EE (MONDO:0013198) is a disease with 1 cohort gene.

At a glance

  • Cohort genes: 1
  • ClinVar variants: 271

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namedilated cardiomyopathy 1EE
Mondo IDMONDO:0013198
MeSHC567683
OMIM613252
DOIDDOID:0110453
UMLSC2750466
MedGen412965
GARD0015639
Is cancer (heuristic)no

Also known as: cardiomyopathy, dilated, 1EE · cardiomyopathy, dilated, type 1Ee · CMD1EE · dilated cardiomyopathy type 1EE · familial isolated dilated cardiomyopathy caused by mutation in MYH6 · MYH6 familial isolated dilated cardiomyopathy

Data availability: 271 ClinVar variants.

Disease family

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disordermuscle tissue disordercardiomyopathyintrinsic cardiomyopathydilated cardiomyopathyfamilial dilated cardiomyopathyfamilial isolated dilated cardiomyopathydilated cardiomyopathy 1EE

Related subtypes (44): dilated cardiomyopathy 1A, dilated cardiomyopathy 3B, dilated cardiomyopathy 1B, dilated cardiomyopathy 1E, dilated cardiomyopathy 1C, dilated cardiomyopathy 1D, dilated cardiomyopathy 1G, dilated cardiomyopathy 1H, dilated cardiomyopathy 1I, dilated cardiomyopathy 1K, dilated cardiomyopathy 1L, dilated cardiomyopathy 1M, dilated cardiomyopathy 1O, dilated cardiomyopathy 1P, dilated cardiomyopathy 1Q, dilated cardiomyopathy 1W, dilated cardiomyopathy 1X, dilated cardiomyopathy 1Y, dilated cardiomyopathy 1Z, dilated cardiomyopathy 2A, dilated cardiomyopathy 1AA, dilated cardiomyopathy 1BB, dilated cardiomyopathy 1CC, dilated cardiomyopathy 1DD, dilated cardiomyopathy 1FF, dilated cardiomyopathy 1R, dilated cardiomyopathy 1S, dilated cardiomyopathy 1GG, dilated cardiomyopathy 1U, dilated cardiomyopathy 1V, dilated cardiomyopathy 1HH, dilated cardiomyopathy 2B, dilated cardiomyopathy 1II, dilated cardiomyopathy 1JJ, dilated cardiomyopathy 1KK, left ventricular noncompaction 8, left ventricular noncompaction 10, dilated cardiomyopathy 1NN, cardiomyopathy, dilated, 2D, cardiomyopathy, dilated, 2E, cardiomyopathy, dilated, 2F, cardiomyopathy, dilated, 2G, cardiomyopathy, dilated, 2c, cardiomyopathy, dilated, 2H

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

271 retrieved; paginated sample, class counts are floors:

201 uncertain significance, 26 conflicting classifications of pathogenicity, 19 benign/likely benign, 18 likely benign, 5 benign, 1 pathogenic, 1 likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
14150NM_002471.4(MYH6):c.2489C>T (p.Pro830Leu)MYH6Pathogenicno assertion criteria provided
3366965NM_002471.4(MYH6):c.5164-2A>GMYH6Likely pathogeniccriteria provided, single submitter
1447754NM_002471.4(MYH6):c.616AAG[1] (p.Lys207del)LOC114827851Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
191724NM_002471.4(MYH6):c.115G>A (p.Val39Met)LOC114827851Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
44474NM_002471.4(MYH6):c.292G>A (p.Glu98Lys)LOC114827851Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
407143NM_002471.4(MYH6):c.4991G>A (p.Arg1664His)LOC126861896Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1284635NM_002471.4(MYH6):c.2717G>A (p.Arg906His)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
14151NM_002471.4(MYH6):c.3010G>T (p.Ala1004Ser)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1432256NM_002471.4(MYH6):c.409G>A (p.Glu137Lys)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
164230NM_002471.4(MYH6):c.3508G>A (p.Glu1170Lys)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
179023NM_002471.4(MYH6):c.3220G>A (p.Asp1074Asn)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1802218NM_002471.4(MYH6):c.5286G>A (p.Thr1762=)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
180424NM_002471.4(MYH6):c.3893C>T (p.Ala1298Val)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
191717NM_002471.4(MYH6):c.3346C>A (p.Arg1116Ser)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
191718NM_002471.4(MYH6):c.2575G>T (p.Gly859Trp)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
228886NM_002471.4(MYH6):c.1336G>A (p.Ala446Thr)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
239163NM_002471.4(MYH6):c.1244G>C (p.Gly415Ala)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
264214NM_002471.4(MYH6):c.5519A>G (p.Lys1840Arg)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
264374NM_002471.4(MYH6):c.3612G>C (p.Glu1204Asp)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
312860NM_002471.4(MYH6):c.3604G>A (p.Val1202Met)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
373555NM_002471.4(MYH6):c.5077G>A (p.Val1693Met)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
44513NM_002471.4(MYH6):c.4505G>A (p.Arg1502Gln)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
44533NM_002471.4(MYH6):c.5293G>A (p.Ala1765Thr)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
520324NM_002471.4(MYH6):c.2929-3C>TMYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
565499NM_002471.4(MYH6):c.3618C>T (p.Gly1206=)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
656980NM_002471.4(MYH6):c.2189T>C (p.Val730Ala)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
800244NM_002471.4(MYH6):c.1486G>A (p.Val496Met)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
860657NM_002471.4(MYH6):c.3447C>T (p.Ser1149=)MYH6Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1023317NM_002471.4(MYH6):c.268A>G (p.Met90Val)LOC114827851Uncertain significancecriteria provided, multiple submitters, no conflicts
1371522NM_002471.4(MYH6):c.244C>T (p.Pro82Ser)LOC114827851Uncertain significancecriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
MYH6Orphanet:154Familial isolated dilated cardiomyopathy
MYH6Orphanet:166282Hereditary sick sinus syndrome
MYH6Orphanet:99103Atrial septal defect, ostium secundum type

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
MYH6HGNC:7576ENSG00000197616P13533Myosin-6clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
MYH6Myosin-6Muscle contraction.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Scaffold/PPI117.3×0.058

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
MYH6Scaffold/PPInoMyosin_head_motor_dom-like, Myosin_tail, SH3_Myosin

Expression context

Cohort genes with no expression data: 0.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
cardiac atrium1
cardiac muscle of right atrium1
vena cava1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
MYH6154tissue_specificyescardiac muscle of right atrium, cardiac atrium, vena cava

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
MYH63,119

Structural data

PDB: 0 · AlphaFold-only: 1 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
MYH6P1353374.91

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 2. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Striated Muscle Contraction1308.6×0.006MYH6
Muscle contraction177.2×0.013MYH6

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
visceral muscle development116852.0×0.001MYH6
regulation of heart growth18426.0×0.001MYH6
atrial cardiac muscle tissue morphogenesis12407.4×0.002MYH6
adult heart development11203.7×0.002MYH6
myofibril assembly11123.5×0.002MYH6
cardiac muscle hypertrophy in response to stress11053.2×0.002MYH6
muscle filament sliding11053.2×0.002MYH6
regulation of the force of heart contraction1991.3×0.002MYH6
striated muscle contraction1842.6×0.003MYH6
ventricular cardiac muscle tissue morphogenesis1702.2×0.003MYH6
cardiac muscle cell development1624.1×0.003MYH6
regulation of heart contraction1495.6×0.003MYH6
regulation of heart rate1468.1×0.003MYH6
ATP metabolic process1468.1×0.003MYH6
cardiac muscle contraction1401.2×0.003MYH6
sarcomere organization1383.0×0.003MYH6
regulation of blood pressure1221.7×0.005MYH6
muscle contraction1208.1×0.005MYH6
in utero embryonic development172.0×0.014MYH6

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
MYH600

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1MYH6

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
MYH60

Clinical trials & evidence

Clinical trials

Clinical trials: 0.